# Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

> **NCT06295562** · PHASE4 · COMPLETED · sponsor: **China Medical University Hospital** · enrollment: 45 (actual)

## Conditions studied

- Obstructive Sleep Apnea of Adult

## Interventions

- **DRUG:** Atomoxetine 80mg combined with oxybutynin 5mg
- **DRUG:** Venlafaxine 37.5mg
- **DRUG:** oxybutynin 5mg combined with trazodone 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06295562
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-05
- **Primary completion:** 2025-10-10
- **Final completion:** 2025-10-22
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295562, "Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06295562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*